The Receptor Occupancy rate and the length of RO time is
The Receptor Occupancy rate and the length of RO time is very different between HIV and Covid-19.
It has to do with RANTES (CCL5).
In HIV, the virus mimics the CCL5 chemokine to gain entrance to the insides of the T-cells where it replicates. This doesn't cause the T-cells to generate all the cell signalling that can set off a Cytokine Storm. Blockade of the CCR5 receptors by leronlimab shuts down HIV and then occupies the receptors at a high rate for 60 days.
With SAR2 and the disease progression that leads to Covid-19 and a Cytokine Storm, the process is quite different.
SARS2 seeks to infect us thru the ACE2 receptors most commonly found in the lungs and gut. Our innate immune system detects the virus almost immediately and sets to work fighting it and calling for help from the rest of the immune system. It does this thru chemical signaling.
As a person's immune system is challenged, you really find out how balanced their immune system is. Do they have the right amounts of each immune component to battle the virus and clean up the debris resulting from the battle? Are there under or over expressions of receptors and cytokines before the battle?
Just how far off is the immune system from homeostasis before it is challenged? How much "energy" does the person have to fight the battle and muster the resources to renew the immune components lost and to take out the garbage?
As we know, Leronlimab's contribution to the immune response is that it controls RANTES, the chemical signalling by CCL5 that can run amok. This keeps the other immune components in better balance and prevents over and under expression of other receptors, but especially CCR5 which is so central in Covid-19 and cancer metastasis.
CCR5 is expressed on the surfaces of many immune components. As these components do battle with the virus and its consequences, many die and become debris. The body collects this debris up and eliminates it, including blockaded CCR5 receptors with leronlimab. The body then tries to generate new immune components with brand new, virgin CCR5 receptors.
This is how you get the fall in receptor occupancy rates. These new CCR5 receptors need to be blockaded with more leronlimab to continue to control RANTES. Otherwise, you have a RANTES rebound and over and under expression of receptors again - not good! The immune system is pulled further away from homeostasis again!
So, under the conditions of fighting the Cytokine Storm, CCR5 occupancy levels lasts for a much shorter time than for HIV. If the levels fall too far, you get rebound of RANTES.
It is my opinion strictly that the best dosing could be achieved with 700mgs IV initially and then 350mgs sub-q every 7 days until the Cytokine storm is over. In longhaulers too, I think every 7 days with 350mgs would keep RO topped off. Just my guess.
I am no expert in any of these matters but I do try to learn from the best. If I reflect their expertise incorrectly, I apologize and hope to be set straight.
21
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...
Continue Reading
Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Top 5 Most Recently Viewed Articles
Gentherm's Financial Performance for Second Quarter 2025 Gentherm, a global innovator in thermal management technologies, reported outstanding financial outcomes for the second quarter of 2025. The company's revenue reached $375 million, underscoring its strength in the automotive sector, particularly within Climate and Comfort Solutions. Record Achievements and New...
Continue Reading
DEALMining Achieves Major User Milestone In a significant accomplishment, DEALMining has proudly announced that its user base has exceeded 6.8 million globally, marking its status as one of the fastest-growing compliant cloud mining platforms in the world. This impressive growth showcases DEALMining's successful outreach across more than 200 countries and regions, as the...
Continue Reading
Investigation into Aehr Test Systems, Inc. Focused on Investor Protection The Law Offices of Frank R. Cruz are actively investigating Aehr Test Systems, Inc. (NASDAQ: AEHR) in light of significant concerns raised regarding the company’s adherence to federal securities laws. This investigation comes as a response to alarming financial disclosures made public by the...
Continue Reading
Vivoryon Therapeutics N.V. Set to Report Financial Outcomes Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is gearing up to unveil its financial results for the entirety of 2024, along with insights into its operational achievements. The highly anticipated announcement is scheduled for April 29, 2025, aiming to shed light on the company’s progress in...
Continue Reading
Understanding the Economic Climate In finance, a stable economy is often described as a "Goldilocks" economy, where conditions are ideal for investments to flourish. Lately, we have witnessed an economy that consistently surpasses expectations, putting worries about downturns to rest. The Search for Economic Balance Investors are keen to find that sweet spot where...
Continue Reading